Exencial Wealth Advisors LLC Acquires 19,089 Shares of IQVIA Holdings Inc. $IQV

Exencial Wealth Advisors LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 47.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,600 shares of the medical research company’s stock after buying an additional 19,089 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in IQVIA were worth $11,321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Asset Dedication LLC increased its holdings in IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the last quarter. Trust Co. of Toledo NA OH purchased a new position in shares of IQVIA during the second quarter valued at about $39,000. J.Safra Asset Management Corp increased its holdings in shares of IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the last quarter. Rothschild Investment LLC lifted its position in shares of IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after buying an additional 124 shares in the last quarter. Finally, NewSquare Capital LLC boosted its stake in IQVIA by 185.3% during the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on IQV. Citigroup lifted their price objective on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. BMO Capital Markets began coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target on the stock. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Truist Financial boosted their target price on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Finally, Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $249.19.

IQVIA Trading Up 0.5%

IQV stock opened at $241.95 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The stock has a market capitalization of $41.20 billion, a price-to-earnings ratio of 33.19, a price-to-earnings-growth ratio of 2.45 and a beta of 1.36. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm’s fifty day simple moving average is $225.53 and its two-hundred day simple moving average is $201.95.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.60% of the stock is owned by company insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.